Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.

Stühlinger, Markus C; Weltermann, Ansgar; Staber, Philipp; Heintel, Daniel; Nösslinger, Thomas; Steurer, Michael

Stühlinger, Markus C; Weltermann, Ansgar; Staber, Philipp; Heintel, Daniel; Nösslinger, Thomas; Steurer, Michael.

Afiliação

Stühlinger MC; University Clinic of Internal Medicine III/Cardiology and Angiology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria. markus.stuehlinger@tirol-kliniken.at.
Weltermann A; Zentrum für Tumorerkrankungen, Ordensklinikum Linz, Linz, Austria.
Staber P; University Clinic of Internal Medicine I, Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Heintel D; 1st Medical Department, Center for Oncology and Hematology, Wilhelminenspital Vienna, Vienna, Austria.
Nösslinger T; 3rd Medical Department, Hematology and Oncology, Hanusch Hospital Vienna, Vienna, Austria.
Steurer M; University Clinic of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.

Wien Klin Wochenschr ; 132(3-4): 97-109, 2020 Feb.

Article em En | MEDLINE | ID: mdl-31414181

Assuntos

Fibrilação Atrial; Doenças Cardiovasculares; Pirazóis/efeitos adversos; Adenina/análogos & derivados; Fibrilação Atrial/induzido quimicamente; Doenças Cardiovasculares/induzido quimicamente; Humanos; Piperidinas; Pirimidinas; Fatores de Risco

Palavras-chave

Anticoagulation; BCR inhibitor; Bleeding; CLL; Chronic lymphocytic leukemia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Fibrilação Atrial / Doenças Cardiovasculares Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google